A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

339

Participants

Timeline

Start Date

May 29, 2014

Primary Completion Date

October 5, 2017

Study Completion Date

October 5, 2017

Conditions
Asthma
Interventions
BIOLOGICAL

Mepolizumab

Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.

DRUG

SOC

Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists

Trial Locations (114)

1020

GSK Investigational Site, Brussels

2305

GSK Investigational Site, New Lambton

3000

GSK Investigational Site, Leuven

3168

GSK Investigational Site, Clayton

4000

GSK Investigational Site, Liège

5042

GSK Investigational Site, Bedford Park

5500

GSK Investigational Site, Mendoza

6009

GSK Investigational Site, Nedlands

7600

GSK Investigational Site, Mar del Plata

9000

GSK Investigational Site, Ghent

10029

GSK Investigational Site, New York

10367

GSK Investigational Site, Berlin

13915

GSK Investigational Site, Marseille

14642

GSK Investigational Site, Rochester

15213

GSK Investigational Site, Pittsburgh

15562

GSK Investigational Site, Rüdersdorf

16132

GSK Investigational Site, Genoa

17027

GSK Investigational Site, Pietra Ligure (SV)

17033

GSK Investigational Site, Hershey

21018

GSK Investigational Site, Vinnytsia

21224

GSK Investigational Site, Baltimore

22299

GSK Investigational Site, Hamburg

23552

GSK Investigational Site, Lübeck

27103

GSK Investigational Site, Winston-Salem

27705

GSK Investigational Site, Durham

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

30173

GSK Investigational Site, Hanover

31707

GSK Investigational Site, Albany

34295

GSK Investigational Site, Montpellier

35013

GSK Investigational Site, Cittadella PD

38610

GSK Investigational Site, Gières

39120

GSK Investigational Site, Magdeburg

43125

GSK Investigational Site, Parma

44093

GSK Investigational Site, Nantes

44195

GSK Investigational Site, Cleveland

54003

GSK Investigational Site, Mykolaiv

55131

GSK Investigational Site, Mainz

55905

GSK Investigational Site, Rochester

59037

GSK Investigational Site, Lille

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

61124

GSK Investigational Site, Kharkiv

63263

GSK Investigational Site, Neu-Isenburg

63571

GSK Investigational Site, Gelnhausen

63739

GSK Investigational Site, Aschaffenburg

66000

GSK Investigational Site, Perpignan

67091

GSK Investigational Site, Strasbourg

69317

GSK Investigational Site, Lyon

71100

GSK Investigational Site, Foggia

75877

GSK Investigational Site, Paris

80131

GSK Investigational Site, Napoli

80206

GSK Investigational Site, Denver

84112

GSK Investigational Site, Salt Lake City

90274

GSK Investigational Site, Rolling Hills Estates

92663

GSK Investigational Site, Newport Beach

94270

GSK Investigational Site, Le Kremlin-Bicêtre

123182

GSK Investigational Site, Moscow

194354

GSK Investigational Site, Saint Petersburg

194356

GSK Investigational Site, Saint Petersburg

454106

GSK Investigational Site, Chelyabinsk

501757

GSK Investigational Site, Donggu Gwangju

2843099

GSK Investigational Site, Rancagua

4270918

GSK Investigational Site, Talcahuano

8380453

GSK Investigational Site, Santiago

92506-0174

GSK Investigational Site, Riverside

06510

GSK Investigational Site, New Haven

Unknown

GSK Investigational Site, San Rafael

S2000DBS

GSK Investigational Site, Rosario

C1424BSF

GSK Investigational Site, Buenos Aires

T2N 4Z6

GSK Investigational Site, Calgary

T6G 2G3

GSK Investigational Site, Edmonton

V5Z 1M9

GSK Investigational Site, Vancouver

R2H 2A6

GSK Investigational Site, Winnipeg

J6E 2B4

GSK Investigational Site, St-Charles-Borromée

H2W 1T8

GSK Investigational Site, Montreal

H2X 2P2

GSK Investigational Site, Montreal

H4J 1C5

GSK Investigational Site, Montreal

G1V 4G5

GSK Investigational Site, Sainte-Foy

625 00

GSK Investigational Site, Brno

775 20

GSK Investigational Site, Olomouc

140 59

GSK Investigational Site, Prague

180 01

GSK Investigational Site, Prague

06156

GSK Investigational Site, Perugia

296-8602

GSK Investigational Site, Chiba

802-0052

GSK Investigational Site, Fukuoka

811-1394

GSK Investigational Site, Fukuoka

370-0615

GSK Investigational Site, Gunma

070-8644

GSK Investigational Site, Hokkaido

319-1113

GSK Investigational Site, Ibaraki

252-0392

GSK Investigational Site, Kanagawa

904-2293

GSK Investigational Site, Okinawa

596-8501

GSK Investigational Site, Osaka

102-0083

GSK Investigational Site, Tokyo

103-0027

GSK Investigational Site, Tokyo

187-0024

GSK Investigational Site, Tokyo

1105 AZ

GSK Investigational Site, Amsterdam

8934 AD

GSK Investigational Site, Leeuwarden

15-044

GSK Investigational Site, Bialystok

31-024

GSK Investigational Site, Krakow

431-070

GSK Investigational Site, Anyang-Si Gyeonggi-do

420-767

GSK Investigational Site, Bucheon City, Gyenggi-do

361-711

GSK Investigational Site, Cheongju, Chungcheongbuk-do

120-752

GSK Investigational Site, Seoul

156-755

GSK Investigational Site, Seoul

443-380

GSK Investigational Site, Suwon-si, Gyeonggi-do

03004

GSK Investigational Site, Alicante

08036

GSK Investigational Site, Barcelona

08041

GSK Investigational Site, Barcelona

08208

GSK Investigational Site, Barcelona

03680

GSK Investigational Site, Kiev

LE3 9QP

GSK Investigational Site, Leicester

BD9 6RJ

GSK Investigational Site, Bradford

PL6 8DH

GSK Investigational Site, Plymouth

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY